Tim Brons: Ledger

Role	Organisation	Sources
	Vida Strategic Partners	Brandon BioCatalyst, Brandon Capital, Brandon BioCatalyst portfolio

Coverage

Stories naming Tim Brons. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Funding announcement

Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers

Pathios Therapeutics has begun treating patients in an Australian Phase 1/2 trial of its GPR65 inhibitor PTT-4256 for advanced solid tumours. Backers to date include Canaan, Brandon Capital and Bristol Myers Squibb.

Brandon BioCatalyst portfolio 21 Nov 2024 Brandon Capital Bristol-Myers Squibb Canaan Grey Wolf Therapeutics M:M Bio Pty Ltd Pathios Therapeutics ThirtyFiveBio Vida Strategic Partners Paul G. Higham Tim Brons Dr Tom McCarthy

Funding announcement

Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers

Pathios Therapeutics has dosed the first patient in a Phase 1/2 trial of its GPR65 inhibitor PTT-4256, run by its Australian team; the company also cites US$58M raised to date.

Brandon Capital portfolio 21 Nov 2024 Brandon Capital Bristol-Myers Squibb Canaan Grey Wolf Therapeutics M:M Bio Pty Ltd Molecule to Medicine (MTM)Pathios Therapeutics ThirtyFiveBio Vida Strategic Partners Paul G. Higham Tim Brons Dr Tom McCarthy

News

Pathios Therapeutics Highlights Role of GPR65 as Critical Innate Immune Checkpoint in the Human Tumor Microenvironment and Reports Anti-Tumor Activity of GPR65 Inhibition During Podium Presentation at AACR 2022

UK cancer biotech Pathios Therapeutics, backed by Canaan Partners and Brandon Capital, presented preclinical data at a US conference showing its GPR65 inhibitor PTT-3213 shrank tumors in mouse models.

Brandon BioCatalyst portfolio 12 Apr 2022 Brandon Capital Canaan Partners Pathios Therapeutics Vida Strategic Partners Stuart Hughes Tim Brons

Tim Brons

Roles

Coverage

Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers

Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers

Pathios Therapeutics Highlights Role of GPR65 as Critical Innate Immune Checkpoint in the Human Tumor Microenvironment and Reports Anti-Tumor Activity of GPR65 Inhibition During Podium Presentation at AACR 2022